Omeros (STU:3O8) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3O8 Omeros Corp STU:3O8
33 GF Score
Price €16.50
! 6 Warning Signs
View Full Analysis

What is Omeros Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:3O8
33GF Score
Omeros Corp STU:3O8
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omeros Business Description

Other Exchanges OMER:USA0KBU:UK
Address 201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
33GF Score

Get the complete analysis for STU:3O8

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.50
Price